Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
| Citation | . “Effect Of Dapagliflozin In Dapa-Hf According To Background Glucose-Lowering Therapy.”. Diabetes Care, pp. 2878-2881. |
| Center | Yale University |
| Author | Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J McMurray V, DAPA-HF Investigators and Committees |
| Abstract |
OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction = 0.39) and across GLT classes. CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF. |
| Year of Publication |
2020
|
| Journal |
Diabetes care
|
| Volume |
43
|
| Issue |
11
|
| Number of Pages |
2878-2881
|
| Date Published |
11/2020
|
| ISSN Number |
1935-5548
|
| DOI |
10.2337/dc20-1402
|
| Alternate Journal |
Diabetes Care
|
| PMID |
33082245
|
| Download citation |